Suki, M.; Imam, A.; Amer, J.; Milgrom, Y.; Massarwa, M.; Hazou, W.; Tiram, Y.; Perzon, O.; Sharif, Y.; Sackran, J.;
et al. SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals 2025, 18, 1118.
https://doi.org/10.3390/ph18081118
AMA Style
Suki M, Imam A, Amer J, Milgrom Y, Massarwa M, Hazou W, Tiram Y, Perzon O, Sharif Y, Sackran J,
et al. SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals. 2025; 18(8):1118.
https://doi.org/10.3390/ph18081118
Chicago/Turabian Style
Suki, Mohamad, Ashraf Imam, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran,
and et al. 2025. "SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic" Pharmaceuticals 18, no. 8: 1118.
https://doi.org/10.3390/ph18081118
APA Style
Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., Lourie, N., Hershko Klement, A., Shibli, S., Safadi, T., Raz, I., Khalaileh, A., & Safadi, R.
(2025). SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals, 18(8), 1118.
https://doi.org/10.3390/ph18081118
